Key facts
- This page summarizes Barbara Klencke's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Sep 2024, 17:26.
Barbara Klencke - 23 Sep 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)
- Reporting relationship
- Director
- Issuer ticker
- TCRX
- Reported as of
- 23 Sep 2024
- Net transaction value
- +$26,450
- SEC form
- 4
- Accepted by SEC
- 24 Sep 2024, 17:26:24 UTC
- Prior SEC filing
- 27 Aug 2024
- Next SEC filing
- 23 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Barbara Klencke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barbara Klencke filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 24 Sep 2024.
Change
- Previous filing in this sequence was filed on 27 Aug 2024.
- Current net transaction value: +$26,450.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRX
transaction
Voting Common Stock
Purchase
- Transaction value
- $26,450
- Shares
- +5,000
- Change %
- +12%
- Price
- $5.29
- Shares after
- 45,000
- Date
- 23 Sep 2024
- Ownership
- Direct
TCRX
holding
Voting Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,000
- Date
- 23 Sep 2024
- Ownership
- By Trust
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares held by the Klencke Huestis Trust, for which the Reporting Person serves as co-trustee along with her spouse. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.